Akums Drugs approves audited FY26 results, recommends dividends, changes senior management
Akums Drugs & Pharmaceuticals · Pharmaceuticals & Biotechnology
Key highlights
- Board approved audited standalone and consolidated results for the year ended March 31, 2026, at its May 14, 2026 meeting.
- Recommended final dividend of Rs. 1.00 and special dividend of Rs. 2.00 per equity share for FY26, subject to AGM approval.
- Appointed V Jagannathan as President – HR and Arvind Srivastava ceased as President – HR, both effective May 14, 2026.
Why it's rated major development: the year-on-year change is 46% (20% or more for adverse news)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Financial Results For The Quarter And Year Ended 31St March, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Akums Drugs & Pharmaceuticals
- Acquisition / mergerMajor developmentAkums Drugs reports Q2 FY27 results and acquires Oriflame India's manufacturing business
- Financial resultsMajor developmentAkums Drugs board approves unaudited results for quarter ended 30 June 2026
- Financial resultsMajor developmentAkums Drugs approves June 2026 quarter results; consolidated tax demand of 560.8 million raised
- Dividend / buyback / bonusMajor development· Adverse for the businessAkums Q4 net profit ₹813.42 million vs ₹1,496.06 million; ₹3 dividend recommended
- Dividend / buyback / bonusMajor development· Adverse for the businessAkums Drugs approves FY 2026 results, appoints auditors, and announces dividends
Other financial results filings this fortnight
- Siddhika Coatings Limited approves joint venture and announces H1 FY 2026 financials
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2026 unaudited financial results
- Financial resultsBrooks LaboratoriesBrooks Laboratories Limited announces Q2 and H1 FY2027 financial results and divestment
- NHC Foods reports Sept 2026 quarter results, 99.98% firm stake, two appointments
- Spectrum Electrical Industries Ltd approves Q2 & H1 results for period ended September 30, 2026
- Dev Labtech Venture reports unaudited half-year results to 30 Sept 2026
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.